Key facts
- Turbine (Drug Discovery)’s last known valuation is $90.2M (Nov 2025).
- It has raised $64.4M; the latest was Later Stage VC ($26.3M) in Nov 2025.
- Notable investors include Accel, AWS Startups, Mercia Ventures, MassMutual Ventures, Crane Venture Partners — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Turbine (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for Turbine (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Turbine (Drug Discovery)
Developer of cancer combination therapies designed to clarify the underlying biology of diseases and develop personalized therapies. The company's combination therapies leverage bioinformatics, network medicine, and artificial intelligence to reliably simulate complex interventions by screening millions of possible drug combinations on simulated cells, enabling cancer patients to receive a low-cost and effective cancer treatment plan.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2015
- Employees
- 104
- Website
- turbine.ai/
- Ownership
- Privately Held (backing)
Turbine (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Turbine (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Turbine (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.